AHG vs FINV

For growth investors, Akso Health Group (AHG) is the stronger pick with 512.

1% revenue growth year-over-year, versus 3. 7% for FinVolution Group (FINV). FinVolution Group (FINV) offers the better valuation at 3. 9x trailing P/E (0. 6x forward), making it the more compelling value choice. Analysts rate FinVolution Group (FINV) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Akso Health Group is actually cheaper at 0.

5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Akso Health Group (AHG) delivered a total return of +42.

4%, compared to -2. 3% for FinVolution Group (FINV). Over 10 years, the gap is even starker: FINV returned -47. 5% versus AHG's -97. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Akso Health Group (AHG) is the lower-risk stock at 0.

14β versus FinVolution Group's 1. 12β — meaning FINV is approximately 685% more volatile than AHG relative to the S&P 500. On balance sheet safety, Akso Health Group (AHG) carries a lower debt/equity ratio of 0% versus 0% for FinVolution Group — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Akso Health Group (AHG) is pulling ahead at 512.

1% versus 3. 7% for FinVolution Group (FINV). On earnings-per-share growth, the picture is similar: FinVolution Group grew EPS 8. 4% year-over-year, compared to -23. 1% for Akso Health Group. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

FinVolution Group (FINV) is the more profitable company, earning 18.

2% net margin versus -913. 4% for Akso Health Group — meaning it keeps 18. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FINV leads at 19. 4% versus -1125. 4% for AHG. At the gross margin level — before operating expenses — FINV leads at 79. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Akso Health Group (AHG) trades at 0.

5x forward P/E versus 0. 6x for FinVolution Group — 0. 1x cheaper on a one-year earnings basis.

In this comparison, FINV (4.

8% yield) pays a dividend. AHG does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Akso Health Group (AHG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

14)). Both have compounded well over 10 years (AHG: -97. 1%, FINV: -47. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AHG is a small-cap high-growth stock; FINV is a small-cap deep-value stock. FINV pays a dividend while AHG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.